title: Developmental minocycline treatment reverses the effects of neonatal immune activation on anxiety- and depression-like behaviors, hippocampal inflammation, and HPA axis activity in adult mice.
abstract: Neonatal infection is associated with increased lifetime risk for neuropsychiatric disorders including anxiety and depression, with evidence showing that dysregulation of the hypothalamic-pituitary-adrenal-(HPA)-axis system may be partly responsible. Preclinical and clinical studies demonstrate that minocycline exhibits antidepressant effects through inhibition of microglial activation and anti-inflammatory actions, and of interest is that recent studies suggest that minocycline alleviates the behavioral abnormalities induced by early-life insults. The current study was designed to determine if developmental minocycline treatment attenuates the neonatal immune activation-induced anxiety- and depression-like symptoms and HPA-axis-dysregulation later in life. To this end, neonatal mice were treated to either lipopolysaccharide or saline on postnatal days (PND) 3-5, then dams during lactation (PND 6-20) and male offspring during adolescence (PND 21-40) received oral administration of minocycline or water via regular drinking bottles. Anxiety- and depression-like behaviors, HPA-axis-reactivity (corticosterone), and hippocampal inflammation (TNF-α and IL-1β) after exposure to stress were evaluated. The results indicated that neonatal immune activation resulted in increased anxiety and depression-like symptoms, HPA-axis-hyperactivity, and elevated the levels of TNF-α and IL-1β in the hippocampus in response to stress in adulthood. Interestingly, developmental minocycline treatment significantly reduced the abnormalities induced by neonatal inflammation in adult mice. In addition, minocycline, regardless of postnatal inflammation, did not have any detrimental effects on the above measured parameters. Considering that minocycline is currently under exploration as an alternative or adjunctive therapy for reducing the symptoms of neurological disorders, our findings suggest that minocycline during development can decrease the behavioral abnormalities induced by early life inflammation in adulthood.
authors.affiliation: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Jafar
authors.initials: J
authors.lastname: Majidi
authors.affiliation: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Morteza
authors.initials: M
authors.lastname: Kosari-Nasab
authors.affiliation: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Laboratory of Neuropsychopharmacology and Psychoneuroimmunology, Hayyan Research Institute, University of Tabriz, Tabriz, Iran. Electronic address: aa.salari@yahoo.com.
authors.forename: Ali-Akbar
authors.initials: AA
authors.lastname: Salari
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001008:Anxiety Disorders / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D003866:Depressive Disorder / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D004195:Disease Models, Animal; D005260:Female; D006624:Hippocampus / Q000187:drug effects* / Q000254:growth & development / Q000276:immunology; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000254:growth & development / Q000276:immunology; D007249:Inflammation / Q000188:drug therapy* / Q000503:physiopathology; D007774:Lactation; D008070:Lipopolysaccharides; D008297:Male; D051379:Mice; D008911:Minocycline / Q000494:pharmacology*; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000254:growth & development / Q000276:immunology
chemical_list: D000900:Anti-Bacterial Agents; D008070:Lipopolysaccharides; D008911:Minocycline
keywords: Affective disorders; Brain development; HPA-axis activity; Hippocampal inflammation; Neonatal infection; Proinflammatory cytokines